North Augusta, SC – December 2025- AmbioPharm, a leading global peptide CDMO, is pleased to announce the appointment of Wen Du as General Manager of AmbioPharm Shanghai. Wen brings more than two decades of experience in the biotech and pharmaceutical industry, with deep expertise in supply chain, procurement, manufacturing, and operations across both global pharmaceutical companies and CDMOs.
In his new role, Wen will lead site operations and support strategic growth in alignment with AmbioPharm’s overall strategy. Prior to joining AmbioPharm, Wen held senior leadership roles at Lonza, including Senior Director, Head of Operations for mammalian monoclonal antibody production and cell banking at the Visp, Switzerland site, and Manufacturing and Supply Chain Director at Lonza’s Guangzhou biologics facility. He also served as Supply Chain Director for Takeda’s Tiajin site and Head of the China Logistics Center.
Wen holds an MBA from Sun Yat-sen University, a bachelor’s degree in International Economics and Trade from Hubei University of Technology, and a second Bachelor’s degree in Pharmacy from China Medical University.
“We are thrilled to welcome Wen to the AmbioPharm leadership team,” said Brian Gregg, CEO. “His global experience and operational insight will be instrumental as we continue to scale our capabilities and deliver high-quality peptide solutions to our partners worldwide.”
About AmbioPharm
AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.